


Brahmer JR, Horn L, Antonia S, Spigel DR, Gandhi L, Sequist LV, Wigginton J, McDonald D, Kollia G, Kumar Gupta A, Gettinger SN; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Vanderbilt-Ingram Cancer Center, Nashville, TN; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; SCRI/Tennessee Oncology, PLLC, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Massachusetts General Hospital Cancer Center, Boston, MA; Bristol-Myers Squibb, Princeton, NJ; Yale University School of Medicine, New Haven, CT. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl; abstr 7509)


www.cancer.org/cancer/analcancer/detailedguide/anal-cancer-survival-rates


https://clinicaltrials.gov/ct2/show/NCT02051868?term=InterAACT&rank=1). International Rare Cancer Initiative


